Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer

Urologic Oncology

Volumn 2, Issue 6, 1996, Pages 191-197

  Tu, Shi Ming ^a   Delpassand, Ebrahim S ^a   Jones, Donnah ^a   Amato, Robert J ^a   Ellerhorst, Julie ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone targeting therapy; Doxorubicin; Prostate cancer; Strontium 89

Indexed keywords

DOXORUBICIN; STRONTIUM 89;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; RADIOISOTOPE THERAPY; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0030805656     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)00013-6     Document Type: Article

References (21)

1. 1. Boring CC, Squires TS, Tong T, Montgomery S, Cancer statistics. Cancer J Clin 1994;44(1):7-26.
2. 2. Muggins C, Hodges CV. Studies of prostatic cancer: Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
3. 3. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiation Oncology Biol Phys 1993;25:805-13.
4. 4. Robinson RG, Spicer JA, Blake GM, et al. Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9(2): 271-81.
5. 5. McEwan AJB, Porter AT, Venner PM, Amyotte G. An evaluation of the safety and efficacy of treatment with Strontium-89 in patients who have previously received wide field radiotherapy. Antibody, Immunoconjugates, and Radiopharmacaeuticals 1990;3(2):91-98.
6. 6. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Brit J Radiol 1991;64:816-22.
7. 7. Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983;1:477-82.
8. 8. Rangel C, Matzkin H, Soloway MS. Experience with weekly doxorubicin (Adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 1992;34:577-82.
9. 9. Byfield JE, Lynch M, Kulhanian F, Chan PYM. Cellular effects of combined adriamycin and X-irradiation in human tumor cells. Int J Cancer 1977;19:194-204.
10. 10. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994; 12(4):683-88.
11. 11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
12. 12. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12(10): 2005-12.
13. 13. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
14. 14. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
15. 15. Sayer J, Ramírez A, Von Eschenbach AC. Retrospective review of prostate cancer patients with lymph node metastases (1968-83). 1992;147(4:2):452a.
16. 16. Mertens WC, Porter A, Reid RH, Powe JE. Strontium-89 and low dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: A preliminary report. J Nucl Med 1992;33:1437-43.
17. 17. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607-15.
18. 18. Gleave ME, Hsieh J-T, Wu H-C, von Eschenbach AC, Chung LWK. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992; 52;1598-1605.
19. 19. Pummer K, Crawford ED, Daneshgari F, Andros B, Pfister S, Miller GJ. Hormonal pretreatment does not affect the final pathological stage in locally advanced prostate cancer. Urology 1994;44:38-42.
20. 20. Tu SM, Huie SR, Song H, et al. Use of ε(γ-glutamyl) lysine as an apoptotic marker in genitourinary cancer patients. Proc ASCO 1996;15:88.
21. 21. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14: 1756-64.